Safety and Efficacy Evaluation of 4-month Regimen of OPC-167832, Delamanid and Bedaquiline in Participants With Drug-Susceptible Pulmonary TB

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This trial will assess the safety and efficacy of OPC-167832 combined with Delamanid and Bedaquiline in subjects with DS-TB administered for 4 months compared to rifampin, isoniazid, ethambutol, pyrazinamide (RHEZ) administered for 6 months
Epistemonikos ID: a0786f05117754a5a7281a082f12e26457f4e875
First added on: May 10, 2024